@triciaot I wish the very best to you on your own journey!

I have a human clinical trial research background in my past life, so I have read a lot about the advances regarding drugging the KRAS linked pathways in PDAC. The latest information that I thought was really exciting (from animal modeling) recently is that turning off the mutated "always on" KRAS pathway may lead to pancreatic tumors becoming more sensitive to chemotherapy. The work has only just begun to use KRAS inhibitors in conjunction with chemo, but I it could be an important development!

Pancreatic cancer is going to be similar to treating HIV/AIDS or breast cancer, where hitting the disease from multiple angles at the same time will be the key to defeating it. While the KRAS inhibitors may not be a cure on their own (as PDAC learns to adapt and evade treatment so well), they are another important piece of the puzzle. I hope all patients get access to RMC-6236 very soon!